Clinical trial
An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day
NCT01357993 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- March 31, 2013
- Enrollment
- 253 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.
attention-deficit / hyperactivity disorder